Cancer treatment firm Sirtex Medical reported that strong sales of its SIR-Spheres drove fiscal fourth-quarter and year-end revenue growth.
For the fourth quarter (end-June 30), Sirtex had $113.4 million in revenue, up 28.5% compared with the fourth quarter of fiscal 2014. Full-year revenue reached $176.1 million, up 36% from the $129.3 million posted last fiscal year.
For the year, Sirtex had net profit of 40.3 million, up from 23.9 million in fiscal 2014.
Global dose sales of its SIR-Spheres yttrium-90 (Y-90) resin microspheres grew 20% in 2015, according to the firm. Sirtex Medical attributed the growth to greater acceptance of the microsphere by the oncology community and increased investment in its sales and marketing structure.
